JP2005508165A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005508165A5 JP2005508165A5 JP2003534444A JP2003534444A JP2005508165A5 JP 2005508165 A5 JP2005508165 A5 JP 2005508165A5 JP 2003534444 A JP2003534444 A JP 2003534444A JP 2003534444 A JP2003534444 A JP 2003534444A JP 2005508165 A5 JP2005508165 A5 JP 2005508165A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- seq
- amino acids
- polynucleotide
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 96
- 108090000765 processed proteins & peptides Proteins 0.000 claims 96
- 102000004196 processed proteins & peptides Human genes 0.000 claims 96
- 150000001413 amino acids Chemical class 0.000 claims 95
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 58
- 102000040430 polynucleotide Human genes 0.000 claims 41
- 108091033319 polynucleotide Proteins 0.000 claims 41
- 239000002157 polynucleotide Substances 0.000 claims 41
- 230000014511 neuron projection development Effects 0.000 claims 24
- 102000005781 Nogo Receptor Human genes 0.000 claims 22
- 108020003872 Nogo receptor Proteins 0.000 claims 22
- 230000001404 mediated effect Effects 0.000 claims 22
- 230000005764 inhibitory process Effects 0.000 claims 19
- 239000012634 fragment Substances 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 10
- 150000007523 nucleic acids Chemical class 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims 4
- 102000005720 Glutathione transferase Human genes 0.000 claims 4
- 108010070675 Glutathione transferase Proteins 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 208000016192 Demyelinating disease Diseases 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- 206010052428 Wound Diseases 0.000 claims 3
- 208000027418 Wounds and injury Diseases 0.000 claims 3
- 230000003376 axonal effect Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 210000002569 neuron Anatomy 0.000 claims 3
- 230000008929 regeneration Effects 0.000 claims 3
- 238000011069 regeneration method Methods 0.000 claims 3
- -1 antibody Substances 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 230000002490 cerebral effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 208000011403 Alexander disease Diseases 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 208000022526 Canavan disease Diseases 0.000 claims 1
- 206010012305 Demyelination Diseases 0.000 claims 1
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 208000028226 Krabbe disease Diseases 0.000 claims 1
- 208000034800 Leukoencephalopathies Diseases 0.000 claims 1
- 102100026784 Myelin proteolipid protein Human genes 0.000 claims 1
- 206010056332 Panencephalitis Diseases 0.000 claims 1
- 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 claims 1
- 102100029826 Reticulon-4 receptor Human genes 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000002491 encephalomyelitis Diseases 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 208000036546 leukodystrophy Diseases 0.000 claims 1
- 230000003458 metachromatic effect Effects 0.000 claims 1
- 238000000520 microinjection Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000023105 myelination Effects 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 208000023516 stroke disease Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 210000004885 white matter Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/972,599 US7119165B2 (en) | 2000-01-12 | 2001-10-06 | Nogo receptor-mediated blockade of axonal growth |
| PCT/US2002/032007 WO2003031462A2 (en) | 2001-10-06 | 2002-10-04 | Nogo receptor-mediated blockade of axonal growth |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005508165A JP2005508165A (ja) | 2005-03-31 |
| JP2005508165A5 true JP2005508165A5 (OSRAM) | 2006-01-05 |
| JP4383869B2 JP4383869B2 (ja) | 2009-12-16 |
Family
ID=25519870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003534444A Expired - Fee Related JP4383869B2 (ja) | 2001-10-06 | 2002-10-04 | 軸索成長のnogoのレセプターを仲介とした妨害 |
Country Status (6)
| Country | Link |
|---|---|
| US (6) | US7119165B2 (OSRAM) |
| EP (1) | EP1451337A4 (OSRAM) |
| JP (1) | JP4383869B2 (OSRAM) |
| AU (1) | AU2002334889B2 (OSRAM) |
| CA (1) | CA2461655A1 (OSRAM) |
| WO (1) | WO2003031462A2 (OSRAM) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1098972T3 (da) * | 1998-07-22 | 2011-01-03 | Smithkline Beecham Ltd | Protein med lighed med neuroendokrinspecifikt protein samt cDNA kodende derfor |
| US7119165B2 (en) * | 2000-01-12 | 2006-10-10 | Yale University | Nogo receptor-mediated blockade of axonal growth |
| NZ525422A (en) * | 2000-10-06 | 2006-09-29 | Biogen Idec Inc | Isolated polynucleotides comprising a nucleic acid which encodes a polypeptide which modulates axonal growth in CNS neurons |
| US7309485B2 (en) * | 2001-12-03 | 2007-12-18 | Children's Medical Center Corporation | Reducing myelin-mediated inhibition of axon regeneration |
| US7745151B2 (en) * | 2002-08-02 | 2010-06-29 | Children's Medical Center Corporation | Methods of determining binding between Nogo receptor and p75 neurotrophin receptor |
| PT1534736E (pt) | 2002-08-10 | 2010-09-07 | Univ Yale | Antagonistas do receptor nogo |
| ATE466870T1 (de) * | 2002-12-06 | 2010-05-15 | Zhi Cheng Xiao | Peptide und deren verwendung in der behandlung von krankheiten des zentralen nervensystems |
| US7842666B2 (en) * | 2002-12-20 | 2010-11-30 | Research Foundation Of City University Of New York | Inhibitors of myelin-associated glycoprotein (MAG) activity for regulating neural growth and regeneration |
| ES2537015T3 (es) | 2003-03-19 | 2015-06-01 | Biogen Ma Inc. | Proteína de unión del receptor de NOGO |
| US7541335B2 (en) * | 2003-04-04 | 2009-06-02 | University Of Rochester | Nogo-receptors and methods of use |
| RS20050774A (sr) * | 2003-04-16 | 2007-12-31 | Biogen Idec Ma Inc., | Antagonisti nogo receptora za tretman stanja sa amiloidnim plakovima |
| CA2525966A1 (en) * | 2003-05-15 | 2004-12-23 | The Board Of Trustees Of The Leland Stanford Junior University | Novel immunomodulating peptide |
| EA008253B1 (ru) * | 2003-08-07 | 2007-04-27 | Байоджен Айдек Ма Инк. | Антагонисты nogo-рецептора |
| WO2005059515A2 (en) * | 2003-12-16 | 2005-06-30 | Children's Medical Center Corporation | Method for treating neurological disorders |
| US8912144B2 (en) * | 2003-12-16 | 2014-12-16 | Children's Medical Center Corporation | Method for treating stroke via administration of NEP1-40 and inosine |
| KR20070052237A (ko) * | 2004-01-30 | 2007-05-21 | 비오겐 아이덱 엠에이 아이엔씨. | 노고 수용체 길항제를 사용한, 도파민성 신경 퇴행을수반하는 상태의 치료법 |
| EP3225633B1 (en) * | 2004-05-21 | 2020-03-25 | The UAB Research Foundation | Variable lymphocyte receptors, related polypeptides and nucleic acids, and uses thereof |
| EP1776136B1 (en) * | 2004-06-24 | 2012-10-03 | Biogen Idec MA Inc. | Treatment of conditions involving demyelination |
| CA2576193A1 (en) | 2004-08-03 | 2006-02-16 | Biogen Idec Ma Inc. | Taj in neuronal function |
| AU2005299974A1 (en) * | 2004-10-01 | 2006-05-04 | Yale University | Nogo-A polypeptide fragments, variant Nogo receptor-1 polypeptides, and uses thereof |
| WO2006056998A2 (en) * | 2004-11-29 | 2006-06-01 | Yeda Research And Development Co. Ltd. | Methods of cell therapy, neurogenesis and oligodendrogenesis |
| WO2007008732A2 (en) * | 2005-07-07 | 2007-01-18 | Yale University | Compositions and methods for suppressing axonal growth inhibition |
| DK1904104T3 (da) | 2005-07-08 | 2013-11-11 | Biogen Idec Inc | SP35-antistoffer og anvendelser heraf |
| US20070026463A1 (en) * | 2005-07-28 | 2007-02-01 | Wyeth | Compositions and methods of mutant Nogo-66 domain proteins |
| US9216212B2 (en) | 2005-08-05 | 2015-12-22 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
| US7951384B2 (en) * | 2005-08-05 | 2011-05-31 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
| CN101248083A (zh) * | 2005-08-25 | 2008-08-20 | 比奥根艾迪克Ma公司 | Nogo受体多肽和多肽片段及其用途 |
| WO2007039256A2 (de) * | 2005-09-30 | 2007-04-12 | Abbott Gmbh & Co. Kg | Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung |
| EP2526968A3 (en) | 2006-01-27 | 2013-05-22 | Biogen Idec MA Inc. | Nogo receptor antagonists |
| EP2023735A4 (en) * | 2006-05-15 | 2011-05-25 | Biogen Idec Inc | USE OF ANTAGONISTS OF THE NOGO RECEPTOR 1 (NGR1) TO PROMOTE THE SURVIVAL OF OLIGODENDROCYTES |
| US20080027001A1 (en) * | 2006-07-07 | 2008-01-31 | Andrew Wood | Nogo receptor functional motifs, peptide mimetics, and mutated functional motifs related thereto, and methods of using the same |
| WO2008013782A2 (en) | 2006-07-24 | 2008-01-31 | Biogen Idec Ma Inc. | Methods for promoting myelination, neuronal survival and oligodendrocyte differentiation via administration of sp35 or trka antagonists |
| WO2008027526A1 (en) * | 2006-08-31 | 2008-03-06 | Biogen Idec Ma Inc. | Methods relating to peripheral administration of nogo receptor polypeptides |
| CN101980603A (zh) * | 2007-10-11 | 2011-02-23 | 比奥根艾迪克Ma公司 | LINGO-1和TrkB拮抗剂的用途 |
| JP5754046B2 (ja) * | 2007-11-08 | 2015-07-22 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | 脱髄を伴う状態の治療におけるlingo−4アンタゴニストの使用 |
| WO2009073141A2 (en) * | 2007-11-28 | 2009-06-11 | Strittmatter Stephen M | Nogo receptor binding small molecules to promote axonal growth |
| US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
| EP2276500A4 (en) * | 2008-03-13 | 2015-03-04 | Univ Yale | REACTIVATION OF AXON GROWTH AND AXON RECOVERY IN CHRONIC REVERSE MARKET INJURIES |
| AU2009269099B2 (en) | 2008-07-09 | 2016-03-10 | Biogen Ma Inc. | Compositions comprising antibodies to LINGO or fragments thereof |
| US8580270B2 (en) | 2008-09-30 | 2013-11-12 | University Of Massachusetts | Respiratory synctial virus (RSV) sequences for protein expression and vaccines |
| BR112012013734A2 (pt) | 2009-12-08 | 2017-01-10 | Abbott Gmbh & Co Kg | anticorpos monoclonais contra a proteína rgm a para uso no tratamento da degeneração da camada de fibras nervosas da retina. |
| SG11201404263TA (en) | 2012-01-27 | 2014-08-28 | Abbvie Deutschland | Composition and method for diagnosis and treatment of diseases associated with neurite degeneration |
| CA2873623C (en) | 2012-05-14 | 2021-11-09 | Biogen Idec Ma Inc. | Lingo-2 antagonists for treatment of conditions involving motor neurons |
| JP2018504400A (ja) | 2015-01-08 | 2018-02-15 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | Lingo‐1拮抗薬及び脱髄障害の治療のための使用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE68923362T2 (de) * | 1988-11-04 | 1996-03-28 | Zuerich Erziehungsdirektion | Wachstumsregelfaktoren für neuriten. |
| CA1341050C (en) * | 1988-11-04 | 2000-07-11 | Martin E. Schwab | Neurite growth regulatory factors |
| US5250414A (en) * | 1988-11-04 | 1993-10-05 | Erziehungsdirektion Of The Canton Zurich | Diagnostic methods using neurite growth regulatory factors |
| WO2000073452A2 (en) | 1999-06-02 | 2000-12-07 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| WO2000037638A2 (en) | 1998-12-22 | 2000-06-29 | Genentech, Inc. | Methods and compositions for inhibiting neoplastic cell growth |
| US5858708A (en) * | 1996-08-12 | 1999-01-12 | Bandman; Olga | Polynucleotides encoding two novel human neuroendocrine-specific proteins |
| WO1999066041A1 (en) | 1998-06-16 | 1999-12-23 | Human Genome Sciences, Inc. | 94 human secreted proteins |
| US7368531B2 (en) * | 1997-03-07 | 2008-05-06 | Human Genome Sciences, Inc. | Human secreted proteins |
| WO2000070050A1 (en) | 1999-05-14 | 2000-11-23 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| PT1490386E (pt) | 1998-03-10 | 2008-11-24 | Genentech Inc | Novos polipéptidos e ácidos nucleicos que os codificam |
| US6962797B2 (en) * | 1998-04-15 | 2005-11-08 | Genentech, Inc. | Nucleic acids encoding PRO615 |
| DK1098972T3 (da) | 1998-07-22 | 2011-01-03 | Smithkline Beecham Ltd | Protein med lighed med neuroendokrinspecifikt protein samt cDNA kodende derfor |
| ES2529196T3 (es) | 1998-11-06 | 2015-02-17 | University Of Zurich | Secuencias de nucleótidos y proteínas de genes Nogo y métodos basados en estas |
| US6152155A (en) | 1998-11-30 | 2000-11-28 | Milligan; Lon | Filter cleaning device |
| CA2347835A1 (en) | 1998-12-01 | 2000-06-08 | Genentech, Inc. | Promotion or inhibition of angiogenesis and cardiovascularization |
| US7041474B2 (en) | 1998-12-30 | 2006-05-09 | Millennium Pharmaceuticals, Inc. | Nucleic acid encoding human tango 509 |
| CA2362427A1 (en) | 1999-03-08 | 2000-09-14 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| CA2361840A1 (en) | 1999-03-08 | 2000-09-14 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| CA2383592A1 (en) | 1999-03-31 | 2000-10-05 | Curagen Corporation | 2384891 acids including open reading frames encoding polypeptides; orfx |
| AU6394400A (en) | 1999-07-30 | 2001-02-19 | Millennium Pharmaceuticals, Inc. | Secreted proteins and uses thereof |
| DE60142023D1 (de) | 2000-01-12 | 2010-06-17 | Univ Yale | Nogo rezeptor-vermittelte blockade des axonalen wachstums |
| US7119165B2 (en) * | 2000-01-12 | 2006-10-10 | Yale University | Nogo receptor-mediated blockade of axonal growth |
| NZ525422A (en) * | 2000-10-06 | 2006-09-29 | Biogen Idec Inc | Isolated polynucleotides comprising a nucleic acid which encodes a polypeptide which modulates axonal growth in CNS neurons |
| JP2005507246A (ja) | 2001-08-27 | 2005-03-17 | ノバルティス アクチエンゲゼルシャフト | Nogoレセプターホモログおよびそれらの使用 |
| EP1440091A1 (en) * | 2001-10-22 | 2004-07-28 | Novartis AG | Nogo receptor homologues and their use |
| US7309485B2 (en) * | 2001-12-03 | 2007-12-18 | Children's Medical Center Corporation | Reducing myelin-mediated inhibition of axon regeneration |
| US20030113325A1 (en) * | 2001-12-03 | 2003-06-19 | Zhigang He | Reducing myelin-mediated inhibition of axon regeneration |
| EP1354892A1 (en) | 2002-04-19 | 2003-10-22 | Centre National De La Recherche Scientifique (Cnrs) | Peptides capable of inducing attraction of the axonal growth and their use for treating neurodegenerative diseases |
| US7745151B2 (en) * | 2002-08-02 | 2010-06-29 | Children's Medical Center Corporation | Methods of determining binding between Nogo receptor and p75 neurotrophin receptor |
| PT1534736E (pt) * | 2002-08-10 | 2010-09-07 | Univ Yale | Antagonistas do receptor nogo |
| RS20050774A (sr) * | 2003-04-16 | 2007-12-31 | Biogen Idec Ma Inc., | Antagonisti nogo receptora za tretman stanja sa amiloidnim plakovima |
| EA008253B1 (ru) * | 2003-08-07 | 2007-04-27 | Байоджен Айдек Ма Инк. | Антагонисты nogo-рецептора |
| CA2535007A1 (en) | 2003-08-07 | 2005-02-24 | Biogen Idec Ma Inc. | Nogo receptor antagonists |
| KR20070052237A (ko) * | 2004-01-30 | 2007-05-21 | 비오겐 아이덱 엠에이 아이엔씨. | 노고 수용체 길항제를 사용한, 도파민성 신경 퇴행을수반하는 상태의 치료법 |
| EP2276500A4 (en) | 2008-03-13 | 2015-03-04 | Univ Yale | REACTIVATION OF AXON GROWTH AND AXON RECOVERY IN CHRONIC REVERSE MARKET INJURIES |
-
2001
- 2001-10-06 US US09/972,599 patent/US7119165B2/en not_active Expired - Lifetime
-
2002
- 2002-10-04 EP EP02800939A patent/EP1451337A4/en not_active Withdrawn
- 2002-10-04 JP JP2003534444A patent/JP4383869B2/ja not_active Expired - Fee Related
- 2002-10-04 AU AU2002334889A patent/AU2002334889B2/en not_active Ceased
- 2002-10-04 CA CA002461655A patent/CA2461655A1/en not_active Abandoned
- 2002-10-04 WO PCT/US2002/032007 patent/WO2003031462A2/en not_active Ceased
-
2006
- 2006-09-06 US US11/516,024 patent/US20080219984A1/en not_active Abandoned
-
2010
- 2010-01-26 US US12/693,940 patent/US8394929B2/en not_active Expired - Fee Related
-
2013
- 2013-03-07 US US13/788,923 patent/US20130171157A1/en not_active Abandoned
- 2013-11-22 US US14/088,158 patent/US20140178392A1/en not_active Abandoned
-
2015
- 2015-07-13 US US14/798,125 patent/US20170174763A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005508165A5 (OSRAM) | ||
| JP2003519481A5 (OSRAM) | ||
| JP6807893B2 (ja) | α−シヌクレインを認識するヒト化抗体 | |
| ES2272093T5 (es) | Composiciones y métodos para incrementar la mineralización de la substancia ósea | |
| US9133272B2 (en) | Bispecific binding agents | |
| EP1181318B1 (en) | Monoclonal antibodies, synthetic and biotechnological derivatives thereof acting as ngf-antagonist molecules | |
| JPH11170A5 (OSRAM) | ||
| KR101484025B1 (ko) | 염증성 질환의 치료를 위한 cxcl13 길항제 및 이의 용도 | |
| CA2872928C (en) | Use of semaphorin-4d binding molecules to promote neurogenesis following stroke | |
| HRP20180516T1 (hr) | Humanizirana protutijela specifična za protofibrilni oblik amiloidnog-beta peptida | |
| JP2009520691A5 (OSRAM) | ||
| EA014525B1 (ru) | Антитела к склеростину и способы их применения | |
| EA015166B1 (ru) | Иммуногенные пептиды склеростина (sost), индуцирующие образование специфических антител | |
| JP2019527194A5 (OSRAM) | ||
| JP2008509658A5 (OSRAM) | ||
| RS57315B1 (sr) | Humanizovana antitela koja prepoznaju alfa-sinuklein | |
| RU2012157270A (ru) | Способ получения антител с улучшенными свойствами | |
| US20190383836A1 (en) | Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases | |
| JP2008509152A5 (OSRAM) | ||
| JPH08504086A (ja) | 背側組織作用因子及び組成物 | |
| JP7449859B2 (ja) | 末梢神経障害又は末梢神経障害若しくはアストロサイト障害が認められる疾患に伴う疼痛の予防又は治療方法 | |
| JP2012508027A5 (OSRAM) | ||
| AU2010209273A1 (en) | Eotaxin-2 (CCL24) inhibitors in inflammatory, autoimmune, and cardiovascular disorders | |
| RU2007146455A (ru) | Варианты эритропоэтина | |
| JP2008539745A5 (OSRAM) |